QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
NASDAQ:FOLD

Amicus Therapeutics Stock Forecast, Price & News

$22.53
+0.14 (+0.63 %)
(As of 11/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$22.03
Now: $22.53
$23.04
50-Day Range
$14.36
MA: $18.89
$22.68
52-Week Range
$6.25
Now: $22.53
$23.19
Volume1.66 million shs
Average Volume2.79 million shs
Market Capitalization$5.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Read More
Amicus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000
Employees584

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$182.24 million
Book Value$1.87 per share

Profitability

Net Income$-356,390,000.00
Net Margins-129.10%

Miscellaneous

Market Cap$5.87 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$22.53
+0.14 (+0.63 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

How has Amicus Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FOLD stock has increased by 179.9% and is now trading at $22.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amicus Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amicus Therapeutics
.

What stocks does MarketBeat like better than Amicus Therapeutics?

Wall Street analysts have given Amicus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Amicus Therapeutics
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.03. Amicus Therapeutics had a negative net margin of 129.10% and a negative return on equity of 65.53%.
View Amicus Therapeutics' earnings history
.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its FY 2020 Pre-Market earnings guidance on Thursday, November, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $256.88 million.

What price target have analysts set for FOLD?

10 brokerages have issued 1-year price objectives for Amicus Therapeutics' stock. Their forecasts range from $12.50 to $31.00. On average, they anticipate Amicus Therapeutics' share price to reach $21.35 in the next year. This suggests that the stock has a possible downside of 5.2%.
View analysts' price targets for Amicus Therapeutics
.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • Mr. John F. Crowley, Chairman & CEO (Age 53, Pay $1.96M)
  • Mr. Bradley L. Campbell M.B.A., Pres, COO & Director (Age 44, Pay $899.2k)
  • Ms. Daphne E. Quimi, Chief Financial Officer (Age 54, Pay $630.45k)
  • Dr. Hung Viet Do, Chief Scientific Officer (Age 52, Pay $637.43k)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 57, Pay $686.59k)
  • Ms. Samantha Prout, VP of Fin., Global Controller & Principal Accounting Officer (Age 42)
  • Dr. Enrique Diloné, Sr. VP of Technical Operations (Age 53)
  • Andrew Faughnan, Director of Investor Relations
  • Mr. Patrik S. Florencio, Sr. VP, Global Chief Compliance & Risk Officer
  • Ms. Diana Moore, Head of Global Corp. Communications

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.64%), BlackRock Inc. (8.10%), Morgan Stanley (4.26%), State Street Corp (3.45%), Jennison Associates LLC (2.07%) and Victory Capital Management Inc. (1.48%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics
.

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Sphera Funds Management LTD., Phoenix Holdings Ltd., Ardsley Advisory Partners LP, Los Angeles Capital Management & Equity Research Inc., Wells Fargo & Company MN, and Perceptive Advisors LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Asset Management Americas Inc., William Blair Investment Management LLC, Point72 Asset Management L.P., Castleark Management LLC, BNP Paribas Arbitrage SA, Victory Capital Management Inc., and Jennison Associates LLC.
View insider buying and selling activity for Amicus Therapeutics
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $22.53.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $5.87 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Amicus Therapeutics employs 584 workers across the globe.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.